Russia Pharmaceutical Pricing & Reimbursement Market Review by GBI Research Published at MarketPublishers.com11 Apr 2012 • by Natalie Aster
LONDON – The scenario of healthcare in Russia, and especially that of pricing and reimbursement of drugs, is in a dynamic phase. The implementation of the new law “On Circulation of Drugs” resulted in the mandatory registration of prices of drugs listed in the Essential Drug List (EDL) in Russia, meaning the government will now regulate drug prices more uniformly. At large, the Russian government’s decision to boost the local pharmaceutical market will lead to the launch of more innovative drugs by domestic pharmaceutical companies. Furthermore, a host of top global pharmaceutical companies are initiating and expanding their production capacities in Russia to make further inroads in this lucrative marketplace.
New market report “Pricing and Reimbursement in Russia - Big Pharma Take Advantage of Reimbursement for Costly Drugs Through the DLO’s Seven Nosologies Program” developed by GBI Research has been recently published by Market Publishers Ltd.
Pricing and Reimbursement in Russia - Big Pharma Take Advantage of Reimbursement for Costly Drugs Through the DLO’s Seven Nosologies Program
Published: April, 2012
Price: US$ 3.500,00
The report provides a comprehensive overview of the healthcare system, and pricing and reimbursement process in Russia, with key data, information and analysis of the steps of the pricing and reimbursement process.
- detailed study of the healthcare scenario in the Russia;
- analysis of the pricing and reimbursement mechanisms in Russia;
- key changes that follow from the implementation of new law “On Circulation of Drugs” in the pricing and reimbursement system;
- details about government bodies which regulate different processes of pricing and reimbursement in Russia;
- details about share of major companies in reimbursement program of Russia;
- insight into various reimbursement programs in Russia.
More new reports by the publisher can be found at GBI Research page.